Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatic Portal System01:21

Hepatic Portal System

5.4K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.4K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

217
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
217
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

185
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185
Liver Regeneration01:24

Liver Regeneration

4.3K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
4.3K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

1.2K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.2K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

257
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
257

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional Liver Imaging Score (FLIS): A Prognostic Biomarker for Acute-on-Chronic Liver Failure and Liver-Related Mortality.

JHEP reports : innovation in hepatology·2026
Same author

Stage-specific drivers of clinical progression in advanced chronic liver disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Characterization of liver disease regression in murine models of liver fibrosis and portal hypertension.

Scientific reports·2026
Same author

Role of spot urine analyses in patients with cirrhosis and ascites as the single first decompensation event.

Annals of hepatology·2026
Same author

Corrigendum to "Improved clinical outcomes of patients with cirrhosis and acute variceal bleeding over the last 2 decades." Gastrointest Endosc 2025;102:733-7.

Gastrointestinal endoscopy·2026
Same author

Decompression with or without Duraplasty for Chiari I and Syringomyelia.

The New England journal of medicine·2026
Same journal

Toward safer rechallenge after severe immune-mediated hepatotoxicity: the need for dynamic and mechanism-informed risk stratification.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same journal

Double immunohistochemistry to detect transglutaminase 2-IgA deposits in celiac children: a multicentre study.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same journal

Effectiveness and safety of mirikizumab in multirefractory ulcerative colitis: analysis from a real-world cohort.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same journal

Novel approaches to liquid biopsy in pancreatic cancer.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same journal

GLP-1 receptor agonists in pediatric obesity.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same journal

An unusual gastric mass in a patient with human immunodeficiency virus infection.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
See all related articles

Related Experiment Video

Updated: Jan 18, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.5K

Angiopoietin 2 levels decrease after HCV-cure and reflect the evolution of portal hypertension.

David Bauer1, Karin Kozbial2, Philipp Schwabl3

  • 1Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria; Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
|April 6, 2022
PubMed
Summary
This summary is machine-generated.

Hepatitis C cure reduces Ang2 and TGF-β, but portal hypertension persists. Angiogenesis mediator Ang2 dynamics reflect portal hypertension and predict decompensation post-treatment.

Keywords:
AngiogenesisCirrhosisHCVHepatic venous pressure gradientSVR

More Related Videos

Study of Viral Vectors in a Three-dimensional Liver Model Repopulated with the Human Hepatocellular Carcinoma Cell Line HepG2
09:13

Study of Viral Vectors in a Three-dimensional Liver Model Repopulated with the Human Hepatocellular Carcinoma Cell Line HepG2

Published on: October 24, 2016

8.5K
Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
10:12

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis

Published on: September 11, 2019

9.1K

Related Experiment Videos

Last Updated: Jan 18, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.5K
Study of Viral Vectors in a Three-dimensional Liver Model Repopulated with the Human Hepatocellular Carcinoma Cell Line HepG2
09:13

Study of Viral Vectors in a Three-dimensional Liver Model Repopulated with the Human Hepatocellular Carcinoma Cell Line HepG2

Published on: October 24, 2016

8.5K
Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
10:12

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis

Published on: September 11, 2019

9.1K

Area of Science:

  • Hepatology
  • Vascular Biology
  • Biochemistry

Background:

  • Portal hypertension (PH) often persists after successful Hepatitis C Virus (HCV) cure.
  • Understanding the molecular mechanisms behind persistent PH is crucial for patient management.

Purpose of the Study:

  • To investigate the impact of HCV cure on cytokines involved in angiogenesis and fibrogenesis.
  • To determine if changes in these cytokines correlate with PH evolution and complications.

Main Methods:

  • Plasma cytokine levels and von Willebrand factor (VWF) were measured.
  • Hepatic venous pressure gradient (HVPG) was assessed before and after HCV cure.
  • Study included 66 patients with pre-treatment PH and 23 controls.

Main Results:

  • HCV cure led to decreased levels of Ang2 and TGF-β, but not other measured cytokines.
  • Altered cytokine profiles in PH patients persisted post-HCV cure.
  • Post-treatment Ang2 levels predicted significant PH and hepatic decompensation.

Conclusions:

  • HCV cure reduces circulating Ang2 and TGF-β, indicating effects on dysangiogenesis and fibrosis.
  • Ang2 dynamics mirror PH progression, suggesting its utility as a non-invasive marker for PH and decompensation risk.
  • Further research is needed to understand the role of persistent cytokine alterations in hindering PH regression.